News archive
Showing 654 results
May 2018
-
Media Release
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response1Kymriah is the only CAR-T… -
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media Release
Alcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
April 2018
-
Media Release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48… -
Media Release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media Release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible- Using patients' self-recorded measurements, FocalView aims to enable… -
Media Release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
March 2018
-
Media Release
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
-- EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial that meaningfully delayed disability progression in typical secondary progressive MS (… -
Media Release
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
February 2018
-
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
- Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows(1)- Study findings show absolute PASI ≤1/≤2/≤3… -
Media Release
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis